j. tabernero e. aranda, a. gomez, b. massutí, j. sastre, a. abad,
DESCRIPTION
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC) the MACRO trial. J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad, - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/1.jpg)
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles
followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in patients (pts) with
metastatic colorectal cancer (mCRC) the MACRO trial
J. TaberneroE. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad, M. Valladares, F. Rivera, Mª J. Safont, E. Diaz-Rubio
On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
![Page 2: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/2.jpg)
Disclosures for J. Tabernero
• Advisory Board member and lecturer for:– Sanofi-Aventis and Roche; – Merck-Serono; Amgen; Imclone; MSD;
Bayer; Onyx; BMS; Boehringer; Celgene; Johnson & Johnson; Novartis; Pfizer
![Page 3: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/3.jpg)
Study Design
ProgressionRCapecitabineOxaliplatin
Bevacizumabx6 cycles q3w
Bevacizumabuntil progression
N=480
N=239
N=241
CapecitabineOxaliplatin
Bevacizumabx6 cycles q3w
CapecitabineOxaliplatin
Bevacizumabuntil progression
![Page 4: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/4.jpg)
Statistical analysis• Sample Size: 470 patients; 235 per arm
– Non-inferiority design – Assuming 10 months as median PFS – Non-inferiority limit of 7.6 m (HR=1.32)– Alpha error = 0.025, one side– Power = 80%– Randomization 1:1
• Efficacy analysis populations:– ITT population: All randomized patients
• Safety population: All patients with, at least, one dose of treatment
• Statistical Analysis:– Kaplan-Meier curves– Cox model hazard ratio (if proportional
assumptions are met)
![Page 5: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/5.jpg)
Study Objectives• Primary endpoint
– Progression free survival* (PFS)
• Secondary endpoints– Overall survival (OS)– Objective tumor response by RECIST – Time to response (TTR)– Response duration– Number of treatment cycles– Safety
* Time from randomization to progression or death
![Page 6: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/6.jpg)
Inclusion Criteria
• Age ≥ 18 years • Histologically confirmed metastatic
colorectal adenocarcinoma• Measurable disease (RECIST)• ECOG ≤ 2 • No previous exposure to bevacizumab• No previous chemotherapy for metastatic
or advanced colorectal cancer• No adjuvant chemotherapy within 6 months
before randomization• No clinically significant cardiovascular
disease
![Page 7: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/7.jpg)
Treatment• XELOX-BEV
– Bevacizumab (BEV): 7.5 mg/kg, iv, d1 q3wk– Oxaliplatin: 130 mg/m2, iv, d1 q3wk – Capecitabine: 1000 mg/m2 oral bid, d1-14 q3wk– Administered until progression of disease, severe
toxicity or consent withdrawal• s/a BEV
– 6 cycles XELOX-BEV q3wk– BEV 7.5 mg/kg, iv, d1 q3wk until progression of
disease, severe toxicity or consent withdrawal
![Page 8: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/8.jpg)
CONSORTPt Selected
N=483
Pt RandomizedN=480
XELOX-BEVN=239
s/a BEVN=241
XELOX-BEVN=238
s/a BEVN=238
ITT
Safety
• 2 Incl / Excl criteria• 1 Other
• 1 Incl / Excl criteria
• 3 Incl / Excl criteria
![Page 9: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/9.jpg)
Patient characteristicsXELOX-BEV
(N=239)s/a BEV (N=241)
Age median, years (range) 63 (30-80)64 (33-
82)
Sex: Male/Female, % 64/36 64/36
ECOG PS 0/1/2 % 49/49/2 59/39/2
Site of primary tumor rectum/colon/both %
31/57/12 23/67/10
Metastases confined to liver % 39 35
Previous Adjuvant CT / RDT % 13/8 17/8
Nº of organs affected 2 (1-5) 3 (1-12)
Surgery of primary tumor % 69 75
![Page 10: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/10.jpg)
Progression Free Survival ITT
LNI: 1.32
Follow-up median months (range) 21.1 (0-40) 20.4 (0-38)
Patients at risk
![Page 11: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/11.jpg)
Overall Survival ITT
Patients at risk
Follow-up median months (range) 21.1 (0-40) 20.4 (0-38)
![Page 12: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/12.jpg)
Confirmed Objective Best Tumor Response (RECIST)Patients
%
Xelox-Bev(N=239)
s/a Bev(N=241)
46 %49 %
Odds ratio (95% CI)= 0.89 (0.62-1.27)
![Page 13: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/13.jpg)
Summary of efficacy
XELOX-BEV (N=239)
s/a BEV(N=241)
HR (CI 95%)
PFS medianEvents %
10.4 (9.3-11.9)67%
9.7 (8.5-10.6)72%
1.11 (0.89–1.37)
OS medianEvents %
23.4 (20.0-26.0)55%
21.7 (18.3-25.1)54%
1.04 (0.81–1.32)
Confirmed OR %
46% 49%0.89 (0.62-
1.27)**Odds Ratio
![Page 14: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/14.jpg)
Surgery XELOX-
BEV (N=239)
s/a BEV (N=241)
Salvage surgery N (%) 28 (11.7) 23 (9.5)
R0 N (%) 21 (8.8) 14 (5.8)
Site:
Liver N (%)
Lung N (%)
Other N (%)
25 (10.5)
2 (0.8)
1 (0.4)
18 (7.5)
2 (0.8)
3 (1.2)
Time to surgery median (months) range
6.8
(3.5-30-0)
8.7
(3.8-17.6)
![Page 15: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/15.jpg)
Chemotherapy: 2nd lines
53 54
29 30
14 15
0
10
20
30
40
50
60
2nd Lines 3rd Lines 4th Lines ormore
XELOX_BEV s/a BEV
Patients%
![Page 16: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/16.jpg)
Safety
XELOX-Bev(N=238)
128 (53.8)
34 (14.2)
4 (1.7)
4 (1.7)
s/a Bev (N=238)
114 (47.9)
48 (19.0)
8 (3.4)
6 (2.5)
n (%)
AEs G3-4
SAEs
AEs leading to death
Death 60 days
Treatment-related AEs
![Page 17: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/17.jpg)
Safety: Treatment-related NCI Grade 3-4* AEs
XELOX-BEV N=238 s/a BEV N=238
N % N %
NEUROPATHY SENSORY 59 24.8 18 7.6
DIARRHEA 26 10.9 33 13.9
HAND FOOT SKIN REACTION 29 12.2 16 6.7
FATIGUE 24 10.5 10 4.2
HYPERTENSION 9 3.8 17 7.1
PROTEINURIA 1 0.4 4 1.7
THROMBOSIS 2 0.8 3 1.3
PERFORATION, GI 2 0.8 1 0.4
BLEEDING 1 0.4 1 0.4
OBSTRUCTION/GI . . 1 0.4
CARDIAC ISCHEMIA . . 1 0.4
* Include grade 5
![Page 18: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/18.jpg)
Treatment compliance
XELOX-BEV
(N=238)
s/a BEV (N=238)
Total cycles administered treatment + maintenance, median (range)
9(1-37)
10(1-53)
Treatment phase cycles, median (range)
6
(1-6)
6
(1-6)
Maintenance phase cycles, median (range)
3
(0-31)
4
(0-47)
![Page 19: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/19.jpg)
Conclusions• This data indicate that a priori specified non-
inferiority cannot be still confirmed, but we can reliably exclude a detriment of larger than 3 weeks in PFS.
• This study suggests that maintenance therapy with single agent BEV may be an appropriate option following induction XELOX-BEV in pts with mCRC.
• Further studies evaluating single agent BEV after standard chemotherapy in mCRC are warranted.
![Page 20: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/20.jpg)
BACK-UP
![Page 21: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/21.jpg)
PFS Non-inferiorityresults interpretation
1
0.89 1.11 1,37
1,32
HR Protocol PFS
HR Macro PFS
XELOX-BEV better
s/a BEV better
LNI
![Page 22: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/22.jpg)
Objective Best Tumor Response (RECIST)
Patients%
62.3 58.9
Odds ratio (95% CI)= 1.15 (0.80-1.67)
46.0 49.0
Odds ratio (95% CI)= 0.89 (0.62-1.27)
![Page 23: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/23.jpg)
Objective Best Tumor Response (RECIST)
Not confirmed Not confirmed
Complete Partial Stable Progression
Patients %Total
(Confirmed)
5.4(3.3)
4.6(4.6)
56.9(42.7) 54.4
(44.4)
25.9 27.4
7.5 5.4
XELOX-BEV
N=239s/a BEV N=241
N (%)
N (%)
Odds Ratio (CI95%)
OR Total149
(62.3%)142
(58.9%)1.15
(0.80 - 1.67)
OR Confirmed110
(4.0%)118
(49.0%)0.89
(0.62 - 1.27)
![Page 24: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/24.jpg)
Safety: NCI Grade 3-4* AEsXELOX-BEV N=238 s/a BEV N=238
N % N %
DIARRHEA 26 10.9 35 14.7
OBSTRUCTION/GI 9 3.8 13 5.5
PERFORATION, GI 4 1.7 2 0.8
NEUROPATHY SENSORY 59 24.8 18 7.6
HAND FOOT SKIN REACTION 29 12.2 16 6.7
FATIGUE 31 13,0 12 5
HYPERTENSION 11 4.6 18 7.6
CARDIAC ISCHEMIA 2 0.8 1 0.4
THROMBOSIS 2 0.8 4 1.7
PROTEINURIA 1 0.4 4 1.7
BLEEDING 3 1.3 2 0.8
* Include grade 5
![Page 25: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/25.jpg)
Safety: NCI Grade 3-4 AEsXELOX-BEV N=238 s/a BEV N238
NCI Grade 3 NCI Grade 4* NCI Grade 3 NCI Grade 4*
N % N % N % N %
NEUROPATHY SENSORY 59 24.8 . . 18 7.6 . .
DIARRHEA 26 10.9 . . 34 14.3 1 0.4
HAND FOOT SKIN REACTION 29 12.2 . . 16 6.7 . .
FATIGUE 30 12.6 1 0.4 12 5.0 . .
HYPERTENSION 11 4.6 . . 18 7.6 . .
OBSTRUCTION/GI 7 2.9 2 0.8 8 3.4 5 2.1
THROMBOSIS 1 0.4 1 0.4 4 1.7 . .
PERFORATION, GI 2 0.8 2 0.8 . . 2 0.8
PROTEINURIA 1 0.4 . . 4 1.7 . .
BLEEDING 2 0.8 1 0.4 2 0.8 . .
CARDIAC ISCHEMIA 2 0.8 . . 1 0.4 . .* Include grade 5
![Page 26: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/26.jpg)
Safety: Treatment-related NCI Grade 3-4 AEs
XELOX-BEV N=238 s/a BEV N=238
NCI Grade 3NCI Grade
4 NCI Grade 3 NCI Grade 4
N % N % N % N %
NEUROPATHY SENSORY 59 24.8 . . 18 7.6 . .
DIARRHEA 26 10.9 . . 32 13.5 1 0.4
HAND FOOT SKIN REACTION 29 12.2 . . 16 6.7 . .
FATIGUE 23 9.7 1 0.4 10 4.2 . .
HYPERTENSION 9 3.8 . . 17 7.1 . .
PROTEINURIA 1 0.4 . . 4 1.7 . .
THROMBOSIS 1 0.4 1 0.4 3 1.3 . .
PERFORATION, GI . . 2 0.8 . . 1 0.4
BLEEDING 1 0.4 . . 1 0.4 . .
OBSTRUCTION/GI . . . . . . 1 0.4
CARDIAC ISCHEMIA . . . . 1 0.4 . .* Include grade 5
![Page 27: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/27.jpg)
Treatment-related AEs leading to death
XELOX-BEV N=238
s/a BEV N=238
N % N %
PERFORATION, GI 2 0.8 2 0.8
UNEXPECTED SUDDEN DEATH 1 0.4 1 0.4
DIARRHEA . . 1 0.4
CARDIOPULMONARY ARREST . . 1 0.4
OBSTRUCTION/GI . . 1 0.4
GASTROINTESTINAL/OTHER 1 0.4 2 0.8
Total 4 1.7 8 (*) 3.4
* Seven deaths cycles 1-6; one death cycle 42
![Page 28: J. Tabernero E. Aranda, A. Gomez, B. Massutí, J. Sastre, A. Abad,](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813a4b550346895da2417c/html5/thumbnails/28.jpg)
Treatment CyclesPatients
%